Head-to-head evidence
ELE-101 vs Lysergide tartrate (LSD)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
ELE-101
Developed by Amandala Neuro Limited and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Lysergide tartrate (LSD) · DT120
Developed by Definium Therapeutics
NCT03866252 · Phase 2 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Next expected readout: September 2027 · NCT07592689 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ELE-101's landscape · Lysergide tartrate (LSD)'s landscape